Manuela Buxo To Become Head of Sanofi’s (SNY) Specialty Care Global Business Unit

Sanofi (NASDAQ:SNY) is one of the Best Dip Stocks to Buy According to Hedge Funds. On February 17, Sanofi (NASDAQ:SNY) announced Manuela Buxo will replace Brian Foard as the Head of its Specialty Care Global Business Unit. Brian Foard, after serving for nearly 9 years, is leaving on February 28 to take on a leadership role elsewhere.

​Manuela Buxo will take over as the Head of Specialty Care Unit on March 1, 2026. She is currently the head of Sanofi’s (NASDAQ:SNY) Global Immunology Alliance Franchise. For the past 2 years, Buxo has been leading the worldwide strategy of Dupixent and brings over 20 years of experience in healthcare. Previously, she has served in Specialty Care roles in Europe and global franchise management.

​Management noted that Brian Foard joined Sanofi in 2017 and later assumed the position of head of Specialty Care. Under his leadership, the unit grew significantly, driven by the launch of Dupixent.

Manuela Buxo To Become Head of Sanofi's (SNY) Specialty Care Global Business Unit

Sanofi (NASDAQ:SNY) researches, produces, and distributes pharmaceutical products. The company’s operations are divided into the Pharmaceuticals, Consumer Healthcare, and Vaccines segments.

While we acknowledge the potential of SNY to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than SNY and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.